Leukemia Research
Volume 36, Issue 3 , Pages 334-341, March 2012

miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia

  • Amanda J. Favreau

      Affiliations

    • Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA
    • The Graduate School of Biomedical Sciences, University of Maine, ME, USA
  • ,
  • Pradeep Sathyanarayana

      Affiliations

    • Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 207 396 8315; fax: +1 207 396 8110.

Received 21 July 2011; received in revised form 21 September 2011; accepted 22 September 2011. published online 24 October 2011.

Abstract 

Aberrations in IL-3, GM-CSF and G-CSF induced signaling are frequently reported in acute myeloid leukemia (AML). Herein, we utilized a unique human myeloid leukemic cell line, AML-193, which responds to all three cytokines to analyze the regulation at microRNA level. Using real-time PCR-based miRNA expression profiling, we investigated miRNA signatures regulated by IL-3, GM-CSF and G-CSF for n=704 miRNAs. We discovered that in addition to regulating specific miRNAs, these cytokines also regulate common set of miRNAs, which includes miR-590-5p, miR-219-5p, miR-15b and miR-628-5p. Taken together, we have identified novel candidate miRNAs that may be instructive during leukemic and normal hematopoiesis.

Keywords: AML-193, AML, miRNA, IL-3, GM-CSF, G-CSF

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(11)00470-X

doi:10.1016/j.leukres.2011.09.027

Leukemia Research
Volume 36, Issue 3 , Pages 334-341, March 2012